Liquid biopsy is a simple and minimally invasive technology that enable testing molecular biomarkers of cancer from a simple blood draw, which may benefit patients who are unable to undergo a surgical biopsy. In spite of several approved PCR-based mutation tests in circulating-tumor DNA (ctDNA) for NCSLC targeted therapies, the next-generation sequencing (NGS), owning to its broad coverage and high sensitivity, has developed rapidly during the last decade and is expected to be widely applied in detection of the targeted biomarkers of cancer.
NovoFocus™ NSCLC CDx Liquid Biopsy Test is an NGS-based companion diagnostic test used as a companion to targeted therapeutic drugs for NSCLC patients. This panel covers all the gene targets as well as its related therapies recommended by NCCN Guidelines (2019v2) for NSCLC, aiming to provide patients with comprehensive guidance for the drug treatments.
|NovoFocus™ NSCLC CDx Liquid Biopsy Test Gene List|
|8 Gene targets for therapeutic use recommended by NCCN Guidelines or approved by FDA.|
|EGFR||Afatinib, Erlotinib, Gefitinib, Dacomitinib, Osimertinib|
|ALK||Alectinib, Ceritinib, Crizotinib, Brigatinib, Lorlatinib|
|8 additional gene targets included in this test|
- NovaSeq 6000, PE150
- All coding exons and ± 20bp intron regions
- 10 calendar days from sample receipt to report delivery